AEON Biopharma (AEON) Stock Price, News & Analysis

Company Overview

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Key Stats

• Today's Range: $0.69 to $0.73
• 50-Day Range: $0.55 to $0.97
• 52-Week Range: $0.38 to $115.57
• Volume: 62,472 shs
• Average Volume: 1.74 million shs
• Market Capitalization: $8.06 million
• P/E Ratio: 3.96
• Dividend Yield: N/A
• Price Target: $360.00
• Consensus Rating: Buy

AEON Biopharma Stock Analysis - MarketRank™

AEON Biopharma scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AEON Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AEON Biopharma is 3.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of AEON Biopharma is 3.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.89.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.08% of the float of AEON Biopharma has been sold short.

Short Interest Ratio / Days to Cover

AEON Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AEON Biopharma has recently decreased by 28.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AEON Biopharma does not currently pay a dividend.

Dividend Growth

AEON Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.08% of the float of AEON Biopharma has been sold short.

Short Interest Ratio / Days to Cover

AEON Biopharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AEON Biopharma has recently decreased by 28.03%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 7 people have searched for AEON on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, AEON Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.86% of the stock of AEON Biopharma is held by insiders.

Percentage Held by Institutions

Only 22.78% of the stock of AEON Biopharma is held by institutions.

AEON Stock Analysis - Frequently Asked Questions

How have AEON shares performed this year?

AEON Biopharma's stock was trading at $38.88 on January 1st, 2025. Since then, AEON stock has decreased by 98.2% and is now trading at $0.7133.

When did AEON Biopharma's stock split?

AEON Biopharma shares reverse split on Wednesday, February 26th 2025.The 1-72 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did AEON Biopharma IPO?

AEON Biopharma (AEON) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of AEON Biopharma?

Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AEON Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

• Today: 8/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AEON
• Previous Symbol: NASDAQ:AEON
• CIK: 1837607
• Web: www.aeonbiopharma.com
• Phone: 754-220-9229
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for AEON Biopharma: $360.00
• High Price Target: $360.00
• Low Price Target: $360.00
• Potential Upside/Downside: +50,369.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $298.12
• Trailing P/E Ratio: 3.96
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -994.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.17

Miscellaneous

• Outstanding Shares: 11,305,000
• Free Float: 74,373,000
• Market Cap: $8.06 million
• Optionable: Not Optionable
• Beta: 0.71